High Levels of Plasma Malondialdehyde,Protein Carbonyl,and Fibrinogen Have Prognostic Potential to Predict Poor Outcomes in Patients With Diabetic Foot Wounds: A Preliminary Communication
Restricted accessOtherFirst published online December, 2008
High Levels of Plasma Malondialdehyde,Protein Carbonyl,and Fibrinogen Have Prognostic Potential to Predict Poor Outcomes in Patients With Diabetic Foot Wounds: A Preliminary Communication
Diabetic foot ulcer (DFU) is the leading cause of lower extremity amputation and is generally known to have poor prognosis. Oxidative stress is considered important in the pathogenesis of chronic wounds. Fibrinogen is a recognized marker in peripheral vascular disease; increasing levels predict an increased mortality and risk of amputation. The aim of this study was to evaluate if plasma malondialdehyde (MDA), protein carbonyl (PC) and fibrinogen levels can be used as prognostic markers in patients with DFU. The study design was prospective, nonrandomized, and controlled. A total of 41 DFU grade 1 and 20 DFU grade 2 patients were studied in this case—control study. Diabetic controls without foot ulcers and healthy controls were also studied. Plasma MDA, PC, and fibrinogen levels were significantly higher in patients with DFU compared with those without ulcers (P < .05) and nondiabetic controls (P < .001). These parameters increased in association with DFU grade (P < .01). Increased levels of plasma fibrinogen, MDA, and PC correlated with worsened outcomes. An augmented oxidative stress and plasma fibrinogen level >300.4 mg% (95% confidence interval, 100% sensitivity, 99.2% specificity) was correlated with a high risk of amputation in DFU.
Wild S., Sicree R., Roglic G., King H., Green A.Global prevalence of diabetes. Diabetes Care. 2004;27;1047-1053.
2.
Diabetes Drafting Group, WHO.Prevalence of small vessel and large vessel disease in diabetic patients from 14 centers. The World Health Organization multinational study of vascular diseases in diabetics. Diabetologia. 1985;28:615-640.
3.
Peripheral arterial disease in people with diabetes: American Diabetes Association Consensus Statement . J Vasc Surg. 2004;39:1356-1357.
4.
Lavery LA, Ashry HR, van Houtum W., Pugh JA, Harkless LB, Basu S.Variations in the incidence and proportion of diabetes related amputations in minorities. Diabetes Care. 1996;19:48-52.
5.
Armstrong DG , Lavery LA, Ouebedeaux TL, Walker SCSurgical morbidity and the risk of amputation due to infected puncture wounds in diabetics versus nondiabetic adults. South Med J. 1997;90:384-389.
6.
Gadepalli R. , Dhawan B., Sreenivas V., Kapil A., Ammini AC, Chaudhry R.A clinico-microbiological study of diabetic foot ulcer in an Indian tertiary care hospital. Diabetes Care . 2006;29:1727-1732.
7.
Beckman JA, Creager MA, Libby P.Diabetes and atherosclerosis epidemiology, pathophysiology and management . JAMA. 2002;287:2570-2581.
8.
Rosen P., Nawroth PP, King G., Möller W., Tritschler HJ, Packer L.The role of oxidative stress in the onset and progression of diabetes and its complications. Diabetes Metab Res Rev. 2001;17:189-212.
9.
Inoguchi T., Li P., Umeda F., et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes. 2000;49:1939-1945.
Zuanetti G. , Latini R., Maggioni AP, Santoro L., Franzosi MGInfluence of diabetes on mortality in acute myocardial infarction: data from GISSI-2 study . J Am Coll Cardiol. 1993;22:1788-1794.
12.
Gu K., Cowie CC, Harris MIDiabetes and decline in heart disease mortality in US adults. JAMA. 1999;281: 1291-1297.
Satoh K.Serum lipid peroxide in CVD determined by new colorimetric method . Clin Chim Acta. 1978;90:37-43.
15.
Levine RL, Williams JA, Stadtman ER, Shacter E.Carbonyl assays for determination of oxidatively modified proteins . Methods Enzymol. 1994;233:346-357.
16.
Wright E., Jr, Seism-Bacon JL, Glass LCOxidative stress in type 2 diabetes: the role of fasting and postprandial glycemia. Int J Clin Pract. 2006;60:308-314.
17.
Guigliano D. , Ceriello A., Paolisso G.Oxidative stress and diabetic vascular complications . Diabetes Care. 1996; 19:257-267.
18.
Ouagliaro L. , Piconi L., Assalone R., et al. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation . Diabetes. 2003;52:2795-2804.
19.
Schiekofer S., Andrassy M., Chen J., Rudofsky G., Schnieder J., Wendt T.Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK and nuclear factor kappaB in PBMCs . Diabetes. 2003;52:621-633.
20.
Del RD, Stewart AJ, Pellegrini N.A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovas Dis. 2005;15:316-328.
21.
Berlett BS, Stadman ERProtein oxidation in ageing, disease and oxidative stress. J Biol Chem. 1997;272: 20313-20316.
22.
Dubry SW, Reaveley DR, Seed M., et al. Risk factors for cardiovascular disease in IDDM. A study of identical twins. Diabetes. 1994;43:831-835.
23.
Vague P., Juhan-Vague I.Fibrinogen, fibrinolysis and diabetes mellitus: a comment. Diabetologia. 1997;40:738-740.
24.
Jones RL, Jovanovic L., Forman S., Peterson CMTime course of reversibility of accelerated fibrinogen disappearance in diabetes mellitus: associations with intravascular volume shifts. Blood. 1984;63:22-30.
25.
Jones RL, Peterson CMReduced fibrinogen survival in diabetes mellitus: a reversible phenomenon . J Clin Invest. 1979;63:485-493.
26.
Stucker M., Moll C., Rudolph T., et al. Fibrinogen adsorption a new treatment option for venous ulcers ? Vasa. 2003;32:173-177.
27.
Collier A., Rumbley AG, Paterson JR, Leach JP, Lowe GDO, Small M.Free radical activity and haemostatic factor in NIDDM patients with and without microalbuminuria. Diabetes. 1992 ;41:909-913.
28.
Knobl P., Schernthaner G., Schack C., et al. Thrombogenic factors are related to urinary albumin excretion in type 1 and type 2 diabetic patients. Diabetologia. 1993;36: 1045-1050.
29.
Ceriello A. , Taboga C., Giacomello R., et al. Fibrinogen plasma levels as marker of thrombin activation in diabetes. Diabetes . 1994;43:430-432.
30.
Ceriello A. , Pirisi M., Giacomello R., et al. Fibrinogen plasma levels as marker of thrombin activation: new insights in the role of fibrinogen as a cardiovascular risk factor. Thromb Haemost. 1994;71:593-595.
31.
Giansante C. , Fiotti N., Caattin L., Da Col PG, Calabresse S.Fibrinogen, D-dimer and thrombin-antithrombin complexes in a random population sample: a relationship with other cardiovascular risk factors. Thromb Haemost. 1994;71:581-586.
32.
Ceriello A. , Giacomello R., Stel G., et al. Hyper-glycemia induced thrombin formation in diabetes: a possible role of oxidative stress . Diabetes . 1995;44:924-928.
